文献速递妇科

BRCA1和BRCA2致病性变异携带者患黑色素瘤风险:系统综述与Meta分析

Risk of melanoma among people with BRCA1 and BRCA2 pathogenic variants: A systematic review and meta-analysis.
PubMed 文献 · Gynecol Oncol · 2025-09-11

该系统综述与Meta分析纳入39项研究,评估BRCA1/2致病性基因变异(PGV)与黑色素瘤的关联。黑色素瘤患者中BRCA1/2 PGV合并患病率为1.7%,携带PGV的合并OR为2.8;但BRCA1 PGV携带者发生黑色素瘤风险与对照无显著差异,BRCA2数据不足以合并分析。

要点

  • 黑色素瘤患者中BRCA1/2 PGV合并患病率为1.7%(95%CI 1.1%-2.6%)。
  • 黑色素瘤患者携带BRCA1/2 PGV的合并OR为2.8(95%CI 1.5-5.4)。
  • BRCA1 PGV携带者黑色素瘤风险与对照无显著差异(OR 1.0,95%CI 0.3-3.6)。

核心结论

  • Meta分析显示黑色素瘤个体携带BRCA1或BRCA2 PGV的合并OR为2.84(原文结论处数值),但有限数据提示BRCA1 PGV携带者发生黑色素瘤的相对风险与对照无差异,BRCA2 PGV数据不足。
  • 作者认为BRCA1/2 PGV可能与黑色素瘤相关,但风险增加幅度可能相对较低。
  • 作者建议需精心设计的队列研究进一步探究BRCA1/2 PGV携带者的黑色素瘤风险 magnitude,并认为提供者在咨询患者时可考虑这一潜在风险。

研究设计与样本

  • 系统综述与Meta分析,遵循PRISMA指南,PROSPERO注册号CRD42024519298。
  • 检索关键电子数据库,纳入评估生殖系BRCA1/2 PGV状态与黑色素瘤关联的研究。
  • 共纳入39项研究。

主要发现

  • 7142例黑色素瘤患者中,BRCA1/2 PGV合并患病率为1.7%(95%CI 1.1%-2.6%)。
  • 2340例黑色素瘤患者与116,501例对照比较,携带BRCA1/2 PGV的合并OR为2.8(95%CI 1.5-5.4),BRCA1单独OR为3.2(95%CI 1.6-6.3),BRCA2单独OR为2.8(95%CI 1.2-6.6)。
  • 14,293例BRCA1/2 PGV携带者中,1.3%(95%CI 0.9-1.8)发生黑色素瘤。
  • 11,154例BRCA1 PGV携带者与11,553例对照相比,黑色素瘤风险无差异(OR 1.0,95%CI 0.3-3.6),BRCA2风险数据不足以进行Meta分析。

临床怎么用

  • 作者认为提供者在咨询患者时可考虑BRCA1/2 PGV与黑色素瘤的潜在关联风险(原文语气为should consider this potential risk when counseling patients)。

局限性

  • 原文结论指出BRCA1 PGV携带者相对风险的数据有限(limited data suggest no difference),BRCA2 PGV相对风险的数据不足(insufficient data)。
  • 原文结论及要点提出需精心设计的队列研究进一步探究BRCA1/2 PGV携带者的黑色素瘤风险幅度(Well-designed cohort studies are warranted)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Patients with BRCA1/2 pathogenic gene variants (PGVs) have an increased risk for breast, ovarian, pancreatic, and prostate cancer, with emerging evidence suggesting an association with melanoma. We aim to evaluate the strength of the melanoma association to guide cancer risk-management recommendations. METHODS: This systematic review and meta-analysis is reported in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines (PROSPERO no.: CRD42024519298). Key electronic databases were searched to identify studies evaluating the association of melanoma with germline BRCA1/2 PGV status. Data from eligible studies were meta-analyzed. RESULTS: Thirty-nine studies were included in this review. Among 7142 patients with melanoma, the pooled prevalence of BRCA1/2 PGVs was 1.7 % (95 % CI 1.1 % - 2.6 %). Among 2340 patients with melanoma compared to 116,501 controls, the pooled odds ratio (OR) of having a BRCA1/2 PGV was 2.8 (95 % CI 1.5-5.4), with similar ORs for BRCA1 (3.2 [95 % CI 1.6-6.3]) and BRCA2 (2.8 [95 % CI 1.2-6.6]) independently. Of 14,293 BRCA1/2 PGV carriers, 1.3 % (95 % CI 0.9-1.8) developed melanoma. The risk of melanoma among 11,154 BRCA1 PGV carriers was not different to that among 11,553 controls (OR 1.0 [95 % CI 0.3-3.6]), with insufficient data to meta-analyze risk for BRCA2. CONCLUSIONS: Our meta-analysis demonstrates that individuals with melanoma have a pooled OR of 2.84 for carrying a BRCA1 or BRCA2 PGV compared to controls; however, limited data suggest no difference in the relative risk of developing melanoma among BRCA1 PGV carriers compared to controls, with insufficient data for relative risk with BRCA2 PGV. These results suggest that although BRCA1/2 PGVs may be associated with melanoma, the magnitude of increased risk is likely relatively low. Well-designed cohort studies are warranted to further investigate the magnitude of melanoma risk among BRCA1/2 PGV carriers and providers should consider this potential risk when counseling patients.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Frontera NM, Ahsan MD, Chandler IR, et al. Risk of melanoma among people with BRCA1 and BRCA2 pathogenic variants: A systematic review and meta-analysis. Gynecol Oncol. 2025. PMID: 40939249. doi:10.1016/j.ygyno.2025.08.030

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。